FDA May Defer Review Of Amendments Under "Complete Response" Reg
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s proposed "complete response" regulation gives the agency the discretion to defer review of an amendment until a subsequent review cycle.
You may also be interested in...
FDA’s "Complete Response" Letters May Not Be Complete Enough For Firms
FDA's "complete response" final regulations finally do away with negative connotations of the "not approvable" label used by the agency since the 1990s, but they will not provide more certainty for sponsors about how to answer FDA's problems with an application
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product